PRESCRIPTION MEDICATION - RX Required
Cytopoint (lokivetmab) is an FDA-approved monoclonal antibody therapy designed to help alleviate the itching associated with atopic dermatitis in dogs. Cytopoint targets and neutralizes interleukin-31 (IL-31), a key cytokine involved in sending itch signals to the brain. This innovative treatment provides fast-acting relief and can improve the quality of life for dogs suffering from allergic dermatitis.
Indications:
- Allergic dermatitis
- Atopic dermatitis
Key Benefits:
- Provides relief from itching within 24 hours
- Long-lasting effect for 4-8 weeks per injection
- Reduces the need for steroids and other medications
- Safe for long-term use in dogs of all ages
- Minimal side effects compared to traditional therapies
Dosage Information:
- Dogs up to 10 lbs (4.5 kg): 10 mg
- Dogs 11 to 20 lbs (5.0-10.0 kg): 20 mg
- Dogs 21 to 30 lbs (10.1-15.0 kg): 30 mg
- Dogs 31 to 40 lbs (15.1-20.0 kg): 40 mg
- Dogs 41 to 50 lbs (20.1-25.0 kg): 50 mg
- Dogs 51 to 60 lbs (25.1-30.0 kg): 60 mg
- Dogs 61 to 80 lbs (30.1-40.0 kg): 80 mg
- Dogs 81 to 100 lbs (40.1-50.0 kg): 90 mg
- Dogs over 100 lbs (over 50.0 kg): 100 mg
Administration:
- Injection: Administer the appropriate dose based on the dog's weight via subcutaneous injection. It is recommended that a veterinarian or trained veterinary staff administer the injection.
- Frequency: Administer once every 4 to 8 weeks, depending on the severity of the condition and the dog's response to therapy.
Precautions:
- Use only as directed by your veterinarian.
- Keep out of reach of children.
- Store in a refrigerator at 2°-8°C (36°-46°F). Do not freeze.
- Not for use in dogs with known hypersensitivity to lokivetmab.
Side Effects:
Cytopoint is generally well-tolerated. Side effects are rare but may include mild reactions at the injection site, lethargy, or gastrointestinal upset.